Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
59:31
Anticoagulants in Older Adults
56:26
Navigating the 2024 PAD Guidelines
8:07
Current opinions on andexanet alfa
1:01:21
HOT TOPICS - ANNEXA-I Trial
32:51
Reversing oral anticoagulants with a focus on Andexanet Alfa
1:01:00
Discussion of 2023 AFib Guidelines
50:55
Choosing Wisely to Achieve Control With BTK Inhibitors in CLL
59:40